<DOC>
	<DOCNO>NCT02954172</DOCNO>
	<brief_summary>A randomized , double blind , multicenter phase3 study .</brief_summary>
	<brief_title>Evaluate Efficacy Safety IBI305 Patients With Advanced Recurrent Non-squamous NSCLC</brief_title>
	<detailed_description>A randomized , double blind , multicenter phase3 study chemotherapy naive patient stage IIIB , IV recurrent NSCLC non-squamous . study randomize 436 patient 1:1 ratio 2 treatment arm . The study divide 4 phase , screening , combination treatment , maintenance follow .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1. sign inform consent form ( ICF ) 2 . Age ≥ 18 year ≤ 70 year , male female 3 . Histologically cytologically document inoperable , local advance ( stage IIIB ) , metastatic ( stage IV ) , recurrent nonsquamous NSCLC ; Mixed tumor categorize accord predominant cell type 4 . Histologically confirm epidermal growth factor receptor ( EGFR ) wild type 5 . At least one measurable lesion accord Response Evaluation Criteria In Solid Tumors（RECISIT） v 1.1 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 7 . Life expectancy ≥ 6 month 8 . Patients childbearing potential must agree use effective contraceptive measure study treatment 6 month receive last study treatment ( e.g . abstinence , sterilization surgery , oral contraceptive , contraception progesterone injection subcutaneous ) . 1 . Prior chemotherapy target therapy another systemic anticancer agent ( e.g. , monoclonal antibody , tyrosine kinase inhibitor ) treatment patient 's current stage disease ( Stage IIIB amenable combined modality treatment , stage IV recurrent disease ) . Prior surgery irradiation permit , provide criterion outline protocol treatment meet . Disease progress within 6 month adjuvant therapy must exclude . 2 . Mixed nonsmall cell small cell carcinoma , mixed adenosquamous carcinoma predominant squamous cell 3 . Histologically cytologically confirm EGFR mutation type , unknown EGFR status reason allow study . 4 . Known hemoptysis within 3 month prior screen blood volume 2.5 mL 5 . Evidence tumor invade major blood vessel image . The investigator local radiologist must exclude evidence tumor fully contiguous , surround , extend lumen major blood vessel ( e.g. , pulmonary artery superior vena cava ) 6 . Evidence brain metastasis , spinal cord compression carcinomatous meningitis history , confirm brain metastasis CT MRI baseline 7 . Radical radiotherapy thorax curative intent within 28 day prior enrollment ; palliative radiotherapy bone lesion outside thoracic region within 2 week prior first dose study treatment . 8 . Serious , nonhealing wound , active ulcer , untreated bone fracture , major surgical procedure within 28 day prior randomization anticipation need major surgery course study . 9 . Minor surgery ( Including insertion indwell catheter ) within 48 hour prior first dose study treatment 10 . Recent current receive treatment Aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory drug ( NSAID ) know inhibit platelet function ( within 10 day prior first dose study treatment ) 11 . Recent current ( within 10 day prior first dose study treatment ) receive treatment oral dose oral parenteral anticoagulant thrombolytic agent . Prophylactic use anticoagulant permit . 12 . History evidence inherit bleed diathesis coagulopathy thrombus 13 . Uncontrolled hypertension ( SBP &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) , prior history hypertensive crisis hypertensive encephalopathy 14 . Clinically significant cardiovascular disease limit active infection ; unstable angina ; stroke transient cerebral ischemia ( within 6 month prior screen ) ; myocardial infarction ( within 6 month prior screen ) ; congestive heartfailure ( New York Heart Association ( NYHA ) class≥ II ) ; serious cardiac arrhythmia , hepatic , renal metabolic disease require medication study . 15 . History peptic ulcer , gastrointestinal perforation , erosive esophagitis , erosive gastritis , inflammatory bowel disease diverticulitis , abdominal fistula intraabdominal abscess within 6 month prior screen 16 . Patient diagnose tracheoesophageal fistula 17 . Clinically significant third space effusion ( e.g. , uncontrolled ascites pleural effusion extraction treatment ) 18 . Pulmonary fibrosis active pneumonia show CT baseline 19 . Active malignancy nonsmall cell lung cancer ( NSCLC ) , treat carcinoma situ cervix , superficial basal cell squamous cell carcinoma , radical surgery localize prostate cancer , radical surgery ductal carcinoma situ within 5 year prior randomization 20 . Known autoimmune disease 21 . Known positive HbsAg hepatitis B virus ( HBV ) DNA drop test peripheral blood ≥ 1 x 103 copy number/L ; If HBsAg positive HBVDNA drop test peripheral blood &lt; 1 x 103 copy number/L , patient consider eligible investigator chronic hepatitis B plateau increase risk 22 . Known positive HIV hepatitis C virus ( HCV ) syphilis 23 . Known allergic disease allergic physique 24 . Treatment investigational agent participation another clinical trial within 30 day prior screen 25 . Known alcoholism drug abuse 26 . Pregnant anticipation pregnant study lactate woman 27 . Known hypersensitivity bevacizumab excipients and/or chemotherapy agent 28 . Other condition investigator think unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>